Where are the biggest points of friction between drug development and commercial manufacturing today, and how can the industry remove them? FUJIFILM Biotechnologies, Systech and Pace Life Sciences discuss.
Orbia Fluor & Energy Materials (Orbia F&EM), has announced a US regulatory milestone for Zephex 152a; its next generation, low global warming potential (low-GWP) propellant for pressurised metered dose inhalers (pMDIs).
Lonza has strengthened its Advanced Synthesis offering to increase phase-appropriate support for the discovery and development of antibody-drug conjugates (ADCs) and other bioconjugates.
European Pharmaceutical Manufacturer sat down with John McDermott, VP scientific consulting at Quotient Sciences, to explore how Translational Pharmaceutics is reshaping the journey from preclinical development to first-in-human studies.
AstraZeneca’s Saphnelo (anifrolumab) has been approved in the European Union (EU) for subcutaneous self-administration as a pre-filled pen for adult patients with systemic lupus erythematosus (SLE) on top of standard therapy.
Dr. Xufeng Sun, VP, manufacturing science and technology at Sharp, discusses how carefully mapping lyophilisation cycles and meticulous fill finish studies help bring oligonucleotide therapies to patients seamlessly.
Boyds’ chief development officer, Dr Nick Meyers, and director of regulatory affairs, Dr Eric Hardter, provide advice and guidance to drug developers and sponsors on de-risking the Investigational New Drug (IND) process.
ACD/Labs, an informatics company that develops and commercialises software in support of digitalised R&D, has released a new two-part white paper series, AI-Digital-Physical Convergence: The Future of DMTA in Drug Discovery and Development.
Aptamer, the developer of next-generation synthetic binders for the life sciences industry, has announced that it has signed a new therapeutic development agreement with Invizius.
ITF Therapeutics, the U.S. affiliate of Italfarmaco, has announced publication of positive long-term safety and efficacy data for givinostat as a treatment for Duchenne muscular dystrophy (DMD).
